JP2014527079A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527079A5 JP2014527079A5 JP2014530315A JP2014530315A JP2014527079A5 JP 2014527079 A5 JP2014527079 A5 JP 2014527079A5 JP 2014530315 A JP2014530315 A JP 2014530315A JP 2014530315 A JP2014530315 A JP 2014530315A JP 2014527079 A5 JP2014527079 A5 JP 2014527079A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- mer
- subject
- subjects
- antifungal agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissue Anatomy 0.000 claims 43
- 229940121375 antifungal agent Drugs 0.000 claims 22
- 239000003429 antifungal agent Substances 0.000 claims 22
- 208000015181 infectious disease Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 10
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 10
- 229940072056 alginate Drugs 0.000 claims 10
- 235000010443 alginic acid Nutrition 0.000 claims 10
- 229920000615 alginic acid Polymers 0.000 claims 10
- 241000233866 Fungi Species 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 8
- 210000004072 lung Anatomy 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 8
- 230000028327 secretion Effects 0.000 claims 8
- 230000003511 endothelial effect Effects 0.000 claims 6
- 210000001508 eye Anatomy 0.000 claims 6
- 210000002307 prostate Anatomy 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 241000228212 Aspergillus Species 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 230000001919 adrenal effect Effects 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 4
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 claims 4
- 210000000981 epithelium Anatomy 0.000 claims 4
- 230000002538 fungal effect Effects 0.000 claims 4
- 210000005228 liver tissue Anatomy 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 210000000944 nerve tissue Anatomy 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 230000002611 ovarian Effects 0.000 claims 4
- 210000004923 pancreatic tissue Anatomy 0.000 claims 4
- 230000001817 pituitary effect Effects 0.000 claims 4
- 150000004291 polyenes Chemical class 0.000 claims 4
- 210000005084 renal tissue Anatomy 0.000 claims 4
- 238000003860 storage Methods 0.000 claims 4
- 210000001550 testis Anatomy 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 230000035899 viability Effects 0.000 claims 4
- 210000000577 adipose tissue Anatomy 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 238000011049 filling Methods 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 claims 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 claims 2
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims 2
- 241000228197 Aspergillus flavus Species 0.000 claims 2
- 241001225321 Aspergillus fumigatus Species 0.000 claims 2
- 241000228245 Aspergillus niger Species 0.000 claims 2
- 241000222122 Candida albicans Species 0.000 claims 2
- 241000222178 Candida tropicalis Species 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000007336 Cryptococcosis Diseases 0.000 claims 2
- 241000221204 Cryptococcus neoformans Species 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 229930195098 Hamycin Natural products 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- AWGBZRVEGDNLDZ-UHFFFAOYSA-N Rimocidin Natural products C1C(C(C(O)C2)C(O)=O)OC2(O)CC(O)CCCC(=O)CC(O)C(CC)C(=O)OC(CCC)CC=CC=CC=CC=CC1OC1OC(C)C(O)C(N)C1O AWGBZRVEGDNLDZ-UHFFFAOYSA-N 0.000 claims 2
- AWGBZRVEGDNLDZ-JCUCCFEFSA-N Rimocidine Chemical compound O([C@H]1/C=C/C=C/C=C/C=C/C[C@H](OC(=O)[C@@H](CC)[C@H](O)CC(=O)CCC[C@H](O)C[C@@]2(O)O[C@H]([C@@H]([C@@H](O)C2)C(O)=O)C1)CCC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O AWGBZRVEGDNLDZ-JCUCCFEFSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims 2
- 229960003942 amphotericin b Drugs 0.000 claims 2
- 229940091771 aspergillus fumigatus Drugs 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 claims 2
- 229960002206 bifonazole Drugs 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 229960002962 butenafine Drugs 0.000 claims 2
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940095731 candida albicans Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- -1 celtaconazole Chemical compound 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229960004022 clotrimazole Drugs 0.000 claims 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 2
- 210000000795 conjunctiva Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000959 ear middle Anatomy 0.000 claims 2
- 229960003913 econazole Drugs 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 229960004884 fluconazole Drugs 0.000 claims 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000003736 gastrointestinal content Anatomy 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 229950006942 hamycin Drugs 0.000 claims 2
- 210000003709 heart valve Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 201000007294 immune system cancer Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229960004849 isoconazole Drugs 0.000 claims 2
- 229960004130 itraconazole Drugs 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000004379 membrane Anatomy 0.000 claims 2
- 229960002509 miconazole Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000000282 nail Anatomy 0.000 claims 2
- 229960003255 natamycin Drugs 0.000 claims 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims 2
- 235000010298 natamycin Nutrition 0.000 claims 2
- 239000004311 natamycin Substances 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 229960000988 nystatin Drugs 0.000 claims 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims 2
- 229960004031 omoconazole Drugs 0.000 claims 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 claims 2
- 230000008520 organization Effects 0.000 claims 2
- 229960003483 oxiconazole Drugs 0.000 claims 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims 2
- 210000004303 peritoneum Anatomy 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 238000006116 polymerization reaction Methods 0.000 claims 2
- 229960001589 posaconazole Drugs 0.000 claims 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims 2
- 238000012545 processing Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000004761 scalp Anatomy 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229960002607 sulconazole Drugs 0.000 claims 2
- 229960000580 terconazole Drugs 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 210000004026 tunica intima Anatomy 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims 2
- 229960004740 voriconazole Drugs 0.000 claims 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 claims 1
- GHJWNRRCRIGGIO-UHFFFAOYSA-N Fosfluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(OP(O)(=O)O)CN1C=NC=N1 GHJWNRRCRIGGIO-UHFFFAOYSA-N 0.000 claims 1
- 102000009097 Phosphorylases Human genes 0.000 claims 1
- 108010073135 Phosphorylases Proteins 0.000 claims 1
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 claims 1
- 229950006373 abafungin Drugs 0.000 claims 1
- 239000003905 agrochemical Substances 0.000 claims 1
- 238000004378 air conditioning Methods 0.000 claims 1
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 claims 1
- 229950006816 albaconazole Drugs 0.000 claims 1
- 229960003204 amorolfine Drugs 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000005757 colony formation Effects 0.000 claims 1
- 239000002361 compost Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 238000005553 drilling Methods 0.000 claims 1
- 239000003651 drinking water Substances 0.000 claims 1
- 235000020188 drinking water Nutrition 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002363 herbicidal effect Effects 0.000 claims 1
- 239000004009 herbicide Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000012770 industrial material Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000003090 pesticide formulation Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 claims 1
- 229950004154 ravuconazole Drugs 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 229960004214 tioconazole Drugs 0.000 claims 1
- 239000003104 tissue culture media Substances 0.000 claims 1
- 239000002699 waste material Substances 0.000 claims 1
- 239000002351 wastewater Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1116010.8 | 2011-09-15 | ||
| GBGB1116010.8A GB201116010D0 (en) | 2011-09-15 | 2011-09-15 | Use of alginate oligomers to enhance the effects of antifungal agents |
| PCT/GB2012/052274 WO2013038197A1 (en) | 2011-09-15 | 2012-09-14 | Use of alginate oligomers to enhance the effects of antifungal agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527079A JP2014527079A (ja) | 2014-10-09 |
| JP2014527079A5 true JP2014527079A5 (enExample) | 2015-11-05 |
| JP6182141B2 JP6182141B2 (ja) | 2017-08-16 |
Family
ID=44908661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530315A Active JP6182141B2 (ja) | 2011-09-15 | 2012-09-14 | 抗真菌剤の効果を高めるアルギネートオリゴマーの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150126467A1 (enExample) |
| EP (1) | EP2755481B1 (enExample) |
| JP (1) | JP6182141B2 (enExample) |
| DK (1) | DK2755481T3 (enExample) |
| ES (1) | ES2798775T3 (enExample) |
| GB (1) | GB201116010D0 (enExample) |
| WO (1) | WO2013038197A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014147869A1 (ja) * | 2013-03-22 | 2014-09-25 | Mizuta Youichi | 植物組織の培養用培地の製造方法及び植物組織の培養方法並びに滅菌処理剤、殺菌処理剤、及び植物組織培養用培地組成物 |
| JP6185157B2 (ja) * | 2013-05-30 | 2017-08-23 | 蘇州科景生物医薬科技有限公司 | 多機能組成物並びにその作製方法及び使用 |
| CN104435823B (zh) * | 2014-11-14 | 2018-02-27 | 西藏月王藏药科技有限公司 | 一种青稞红曲藏药饮片的制备方法 |
| CN110198959B (zh) | 2017-01-03 | 2023-03-28 | 北卡罗米纳大学查佩尔希尔分校 | 释放一氧化氮的海藻酸盐作为可生物降解抗菌支架和相关方法 |
| JP7112706B2 (ja) * | 2017-01-16 | 2022-08-04 | 御木本製薬株式会社 | 抗菌性組成物並びに該抗菌性組成物を配合した皮膚外用剤 |
| US10548948B2 (en) * | 2017-03-02 | 2020-02-04 | The United States Of America As Represented By The Secretary Of The Navy | Methods of treating fungal infections |
| EP3600338A4 (en) | 2017-03-28 | 2020-10-28 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES |
| JP2021503029A (ja) | 2017-11-15 | 2021-02-04 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗菌性足場としての一酸化窒素放出性超分岐化合物およびそれに関する方法 |
| CN107904179B (zh) * | 2017-12-18 | 2020-10-23 | 云南天禾地生物科技股份有限公司 | 一株兼具植物促生长和抗病性的罗伦隐球酵母及其应用 |
| AU2019231712B2 (en) | 2018-03-06 | 2025-04-10 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
| US20210030891A1 (en) * | 2018-03-19 | 2021-02-04 | Algipharma As | Use of alginate oligomers to enhance the translocation of micro/nanoparticles across mucus layers |
| CN113383019B (zh) | 2018-12-28 | 2023-11-17 | 北卡罗来纳大学教堂山分校 | 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法 |
| EP3995317A1 (en) * | 2019-04-08 | 2022-05-11 | Main Choice Paper Products Limited | Germ-repellent book and food paper packaging, and method of manufacture |
| EP3837977A1 (en) | 2019-12-19 | 2021-06-23 | Université de Bourgogne | Use of alginates oligomers to improve plant protection against pathogens |
| DE102020101110A1 (de) | 2020-01-17 | 2021-07-22 | Beuth Hochschule Für Technik Berlin | Antimykotische Aktivitäten von Hydrogelen auf Basis von Polysacchariden |
| CN111701013A (zh) * | 2020-07-02 | 2020-09-25 | 深圳市恩瑜生物科技有限公司 | 一种具有治疗真菌感染的外用药物及制备方法 |
| CN113430125B (zh) * | 2021-07-27 | 2022-11-08 | 塔里木大学 | 一种高酯化力与糖化力的混合菌剂及其培养方法 |
| CN114009440A (zh) * | 2021-11-22 | 2022-02-08 | 兰州大学 | 阿巴芬净在防治农业病原菌中的用途 |
| US20230346101A1 (en) * | 2022-04-29 | 2023-11-02 | Distinct Dermatology Inc. | Treatment of fungal nail infection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991011205A1 (en) | 1990-01-23 | 1991-08-08 | Trancel Corporation | Mannuronic acid containing alginate wound healing composition and method |
| US5169840A (en) | 1991-03-27 | 1992-12-08 | Nobipols Forskningsstiftelse | Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation |
| US5217493A (en) * | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
| CA2106609A1 (en) | 1992-09-28 | 1994-03-29 | Irene Yeatman Aldridge | Proteases to inhibit and remove biofilm |
| GB9221163D0 (en) | 1992-10-08 | 1992-11-25 | Nobipol And Protan Biopolymer | Dna compounds |
| JPH093031A (ja) * | 1995-04-17 | 1997-01-07 | Mitsubishi Chem Corp | ヒドロキサム酸誘導体並びにそれを含有する農園芸用殺菌剤 |
| EP0807631B1 (en) * | 1996-05-15 | 2003-03-12 | Sankyo Company Limited | Tricyclic compounds having fungicidal activity, their preparation and their use |
| NO305033B1 (no) | 1997-05-09 | 1999-03-22 | Algipharma As | Fremgangsmate for fremstilling av uronsyreblokker fra alginat |
| US7494669B2 (en) | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
| NO326145B1 (no) | 2001-11-30 | 2008-10-06 | Fmc Biopolymer As | Fremgangsmate for a stimulere vektokning hos pattedyr, fugler og krypdyr. |
| NO20023581D0 (no) | 2002-07-26 | 2002-07-26 | Fmc Biopolymer As | Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat |
| GB2430881B (en) | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
| GB0707096D0 (en) | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
| ES2625866T3 (es) * | 2007-11-27 | 2017-07-20 | Algipharma As | Uso de oligómeros de alginatos para combatir las biopelículas |
-
2011
- 2011-09-15 GB GBGB1116010.8A patent/GB201116010D0/en not_active Ceased
-
2012
- 2012-09-14 ES ES12766466T patent/ES2798775T3/es active Active
- 2012-09-14 EP EP12766466.2A patent/EP2755481B1/en active Active
- 2012-09-14 DK DK12766466.2T patent/DK2755481T3/da active
- 2012-09-14 US US14/345,224 patent/US20150126467A1/en not_active Abandoned
- 2012-09-14 JP JP2014530315A patent/JP6182141B2/ja active Active
- 2012-09-14 WO PCT/GB2012/052274 patent/WO2013038197A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527079A5 (enExample) | ||
| EP2755481B1 (en) | Use of alginate oligomers to enhance the effects of antifungal agents | |
| Malani et al. | Changing epidemiology of rare mould infections: implications for therapy | |
| ES2442793T3 (es) | Tratamiento de Acinetobacter con oligómeros de alginato y antibióticos | |
| CN101473009A (zh) | 臭氧化表面活性剂 | |
| CN109154603A (zh) | 用于治疗真菌感染的给药方案 | |
| CN108042578A (zh) | 一种含有复合益生菌成分的保健阴道凝胶 | |
| US11311635B2 (en) | Ultrasonic couplant spray | |
| TW202024058A (zh) | 用於治療真菌感染之化合物及方法 | |
| CN107873712A (zh) | 咪唑类抗真菌医药作为杀菌剂在农作物病害防治上的新用途 | |
| CN110448554A (zh) | D-青霉胺联合氟康唑在制备抗真菌产品中的应用 | |
| JP2015199682A (ja) | 多剤耐性真菌に有効な抗真菌剤 | |
| AU2021293911B2 (en) | Compounds and methods for treating fungal infections | |
| EP2650285A1 (en) | Fungicide | |
| CN102150660B (zh) | 一种含有四氟醚唑的杀菌组合物 | |
| CN114209835A (zh) | 一种念珠菌属感染疾病的治疗药物 | |
| CN101999365A (zh) | 一种含有丙环唑的杀菌组合物 | |
| CN102696664A (zh) | 一种含嘧菌胺与三唑类的杀菌组合物 | |
| CN101743977B (zh) | 一种含己唑醇与噻菌灵的杀菌组合物 | |
| CN102488692B (zh) | 乙酰乳酸合成酶抑制剂化合物作为制备抗真菌药物的应用 | |
| CN101953343B (zh) | 一种含抑霉唑与腈菌唑的杀菌组合物 | |
| CN101595878A (zh) | 一种含粉唑醇与嘧菌环胺的杀菌组合物 | |
| CN101889578B (zh) | 一种含抑霉唑与氟硅唑的杀菌组合物 | |
| BR102024006284A2 (pt) | Usos de composição contendo oligossacarídeos cíclicos antibiofilme e/ou antifúngica | |
| CN101999384B (zh) | 一种含十三吗啉的杀菌组合物 |